Twitter | Search | |
Joel Jean-Mairet
@ Ysios Capital / investor and entrepreneur, co-founder & CEO GLYCART, company that discovered FDA approved Gazyva/GA101 for CLL
60
Tweets
98
Following
98
Followers
Tweets
Joel Jean-Mairet retweeted
Ysios Capital May 20
Reply Retweet Like
Joel Jean-Mairet retweeted
Biocat May 21
Raúl Martín-Ruiz d' explica al organitzat per amb al la història d'inversió de Stat-DX, des de la seva 1a aposta per l'empresa fins a l'exit
Reply Retweet Like
Joel Jean-Mairet retweeted
Biocat May 21
"Per poder atreure inversors internacionals, les startups han de tenir molt en compte què demanda el mercat i les empreses farmacèutiques", recorda Raúl Martín-Ruiz d' al de i al
Reply Retweet Like
Joel Jean-Mairet retweeted
@EstebanezLab May 21
What an amazing positive feedback we received today at after our pitch! A fantastic opportunity to present our innovative project. Huge thanks to and
Reply Retweet Like
Joel Jean-Mairet retweeted
Biocat May 21
"A Catalunya les coses s'estan fent molt bé, incloent-hi la implicació del govern i d'institucions molt compromeses com . Tenim success stories i és qüestió de temps i perseverança seguir creixent ", auguea Raul Martín-Ruiz
Reply Retweet Like
Joel Jean-Mairet retweeted
diariomedico May 16
La inversión de 'start-ups' biomédicas en crece un 1,9% en 2018 respecto al año anterior
Reply Retweet Like
Joel Jean-Mairet retweeted
Ysios Capital May 20
🔝🔝Estamos con ⁦⁩ en el workshop de
Reply Retweet Like
Joel Jean-Mairet retweeted
startupticker May 7
Founders on stage. Joel Jean-Mairet and Pablo Umana, founders of Glycart, and Christian Klein from Roche receive one of the Swiss Biotech Success Stories Awards at
Reply Retweet Like
Joel Jean-Mairet retweeted
CataloniaBio & HealthTech Mar 11
🔝 Biosuccess 👉🏻 : "When we started in 2008 at , there weren't any specialised investors and hardly any companies were being created. Ten years later, we have success stories and international recognition"
Reply Retweet Like
Joel Jean-Mairet retweeted
Ysios Capital Apr 26
Hoy estamos con en el en el panel "De emprendedor a gestor de venture capital". Gracias por contar con
Reply Retweet Like
Joel Jean-Mairet retweeted
Ysios Capital May 8
🔝Congrats for being awarded with the Success Story award !
Reply Retweet Like
Joel Jean-Mairet retweeted
Michael Gilman 13 May 17
Deeply, truly committed to patients and a ferocious believer in and supporter of the life science community. Gone well before his time.
Reply Retweet Like
Joel Jean-Mairet retweeted
Ysios Capital 29 Mar 17
Hoy Julia Salaverria participa en la mesa redonda en la presentación informe del venture capital en España preparado por
Reply Retweet Like
Joel Jean-Mairet retweeted
Catalan Government 31 Mar 17
President visits the new Europastry production plant in New Brunswick on the occasion of the Catalan company's 30th anniversary
Reply Retweet Like
Joel Jean-Mairet 22 Mar 17
BioClin scores a $30M raise from marquee investors to fuel mid-stage work on a new cancer drug -
Reply Retweet Like
Joel Jean-Mairet 6 Feb 17
Early detection of ocular melanoma, combined with the administration of AU-011 as a potential vision-sparing...
Reply Retweet Like
Joel Jean-Mairet retweeted
Julie Gralow 8 Dec 16
Exciting discussion about bone mets w/ my bone colleagues at poster session!
Reply Retweet Like
Joel Jean-Mairet 4 Jul 16
Pedazo acuerda TiGenix/Takeda!
Reply Retweet Like
Joel Jean-Mairet 26 Apr 16
AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial
Reply Retweet Like
Joel Jean-Mairet 18 Feb 16
Buen artículo Guillermo! Habrá más este año ...
Reply Retweet Like